(NASDAQ: MBX) Mbx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.6%.
Mbx Biosciences's earnings in 2025 is -$80,495,000.On average, 10 Wall Street analysts forecast MBX's earnings for 2025 to be -$118,524,116, with the lowest MBX earnings forecast at -$124,092,002, and the highest MBX earnings forecast at -$103,724,318. On average, 10 Wall Street analysts forecast MBX's earnings for 2026 to be -$138,141,932, with the lowest MBX earnings forecast at -$201,539,492, and the highest MBX earnings forecast at -$99,009,576.
In 2027, MBX is forecast to generate -$173,062,452 in earnings, with the lowest earnings forecast at -$220,991,170 and the highest earnings forecast at -$107,496,111.